• Enliven Therapeutics flagged additional positive Phase 1 data for ELVN-001 in previously treated chronic myeloid leukemia, with updated results scheduled for oral presentation at EHA 2026 on June 11.
• Some findings were already presented in January 2026, with new disclosures set to extend follow-up and add patients.
• ELVN-001 continued to show meaningful anti-disease activity in a heavily pretreated population, including patients previously treated with asciminib.
• Safety profile remained favorable, with most patients staying on therapy and relatively few stopping treatment due to side effects.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605120953PR_NEWS_USPR_____LA57045) on May 12, 2026, and is solely responsible for the information contained therein.